Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Actos ruling the shape of things to come?

This article was originally published in Scrip

Executive Summary

In what could be seen as either a worrying precedent or significant patient victory, a US court has awarded a total of $6.5 million in compensatory damages to a plaintiff and his wife in the first case to come to trial on the bladder cancer risks of Takeda's former blockbuster diabetes drug Actos (pioglitazone).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021213

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel